Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,132.40
(
0.00%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.63
(
-1.02%
)
Bitcoin
73,875.91
(
-0.09%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 73881

Thursday, 04/16/2009 6:04:05 PM

Thursday, April 16, 2009 6:04:05 PM

Post# of 257253
VRTX just started a second 3-day VCH-222 phase-1 monotherapy study in 32 treatment-naïve genotype-1 patients. VRTX’s CMO said on today’s CC that the previous 3-day VCH-222 study that VRTX touted as the main impetus for the ViroChem acquisition (#msg-36022752) contained only 5 patients!

Today’s CC made it crystal clear that VCH-222 is VRTX’s lead polymerase inhibitor; VCH-759, although further advanced than VCH-222, has been relegated to backup status and will be pursued only if VCH-222 falters.

Today’s PR (including the 1Q09 financial results):
http://finance.yahoo.com/news/Vertex-Pharmaceuticals-bw-14949364.html


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now